Become a strategic partner for the industrialisation and commercialisation
of this innovation through an operating licence.

MIR

New therapeutic approach based on microRNA for the treatment of intestinal inflammation associated with IBD and other forms of severe intestinal inflammation

Investment: 634k€

Scope: Health

Scientific field(s): Biology and medicinal chemistry

Institution(s): Université Paris-Saclay - INRAE

Development: Technology to be marketed

#Inflammation #ClostridiumDifficile #MiRNA

#1

Fine modulation of local inflammation

#2

Acts on several effectors of the inflammatory response

#3

High therapeutic index

#4

Complementary to standard treatment protocols

USE CASES

CDI, a nosocomial disease in most cases affecting 160,000 people/year in Europe and 450,000 in the United States, is responsible for approximately 4,000 and 29,000 deaths/year, respectively.
Use as an adjunct to standard antibiotic therapy.
Significant medical need to control intestinal inflammatory response.

APPLICATIONS

miRNA enabling a reduction in local inflammatory response
Treatment of patients developing Clostridioides difficile infection (CDI).

ADVANTAGES

Significant reduction in asynchronies between the patient and the ventilator.